About Us
Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, HIV, and liver cancer.
Its lead clinical candidate, ABX464, has demonstrated the potential to treat inflammatory diseases and to reduce the viral reservoir in HIV.
Pipeline
With five programs in clinical testing, a trial in Crohn’s disease to start and three projects in research and preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.
Clinical Programs
-
ABX464 UC
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in a Phase 2a clinical trial, ABX464-101, to treat ulcerative colitis (UC). Patients who completed the induction study had the option to roll over into a 12-month open-label extension study, ABX464-102, in which 22 out of 23 eligible patients were enrolled.
Read More -
ABX464 Crohn’s Disease
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory efficacy in a completed Phase 2a induction study as well as a 24-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC).
Read More
Due the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that ABX464 will also show beneficial effects in patients suffering from CD. -
ABX464 Rheumatoid Arthritis
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in a completed Phase 2a induction study as well as a 12-month maintenance study in patients with moderate-to-severe ulcerative colitis (UC). In addition to the clinical observations in UC patients, Abivax generated promising pre-clinical data from collagen-induced arthritis animal models.
Read More -
ABX464 HIV
ABX464 is an oral, first-in-class, novel, small molecule inhibiting HIV replication through an entirely new mechanism of action. For the first time in the treatment of HIV, this molecule could reduce or eliminate the viral reservoirs, and thus potentially deliver a long-lasting virological suppression in HIV-patients.
Read More -
ABX196 HCC
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.
Read More
R&D Assets

Science
Based on innovative research driven by the idea of stimulating the body’s natural immune system mechanisms to cure diseases.

Investors
Abivax SA has been listed on the Paris stock exchange since June 26, 2015.
Symbol
ABVX
